PATENT CLAIM ANALYSIS

Application Number: 16055659
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2019-08
Patent Classification: ["424", "139100"]

Abstract:
The subject invention relates to isolated proteins, particularly monoclonal antibodies, which bind to the Nogo-66 receptor. Specifically, these antibodies have the ability to inhibit the binding of the natural ligand of the Nogo-66 receptor and neutralize the Nogo-66 receptor. These antibodies or portions thereof of the invention are useful for detecting NgR and for inhibiting NgR activity, for example in a human suffering from a disorder in which NgR or Nogo-66 activity is detrimental.

Claim (Index 47):
The method of  claim 46 , wherein the disorder comprises neurological diseases selected from the group consisting of Amytropic Lateral Sclerosis, Brachial Plexus Injury, Brain Injury, including traumatic brain injury, Cerebral Palsy, Friedrich's Ataxia, Guillain Barre, Leukodystrophies, Multiple Sclerosis, Post Polio, Spina Bifida, Spinal Cord Injury, Spinal Muscle Atrophy, Spinal Tumors, Stroke, and Transverse Myelitits.

Metadata:
- Claim Count in Document: 2.0
- Percentile: 96.0
- Lexical Diversity: 1.6875
- Patent Class: 424.0
- Transitional Phrase Type: closed
- Component Type: 1
- Foreign Priority: False
- Related Applications: ['11943770', '14989532', '14013916', '11983775', '12693940']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7852547580668829
- 35 USC 102 Novelty (BERT): 0.5534009912109029
- Combined Prediction Score: 0.762069381381285
- Mean Citation Score: 391.015772
- Max Citation Score: 460.20157
- Similarity Product: 262.15856717723494

Labels:
- Claim Label 101: 1
- Claim Label 102: 0
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 0
- Label 101 Adjusted: 0

Dataset: test